Welcome to our dedicated page for CNST news (Ticker: CNST), a resource for investors and traders seeking the latest updates and insights on CNST stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CNST's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CNST's position in the market.
Constellation Pharmaceuticals will host a conference call on February 24, 2021, at 8:00 AM EDT, to discuss its fourth quarter 2020 results and provide a business update. The event will be accessible via live webcast on the company's website. Interested participants can join the Q&A session by calling (877) 473-2077 (domestic) or (661) 378-9662 (international), using conference ID 6971724. Constellation focuses on developing novel therapeutics for cancer, including the BET inhibitor pelabresib and EZH2 inhibitor CPI-0209.
Constellation Pharmaceuticals (Nasdaq: CNST) appointed Brendan Delaney as Chief Commercial Officer effective January 11, 2021. He is tasked with establishing the commercial organization and pre-launch preparations for CPI-0610, a promising therapy for myelofibrosis. Delaney brings over 25 years of experience in hematology and oncology commercialization, with prior roles at Immunomedics and Celgene. His expertise is expected to drive the potential launch of CPI-0610, which aims to address unmet medical needs in the treatment of myelofibrosis.
Constellation Pharmaceuticals (Nasdaq: CNST) will have CEO Jigar Raythatha present a company overview at the J.P. Morgan Healthcare Conference on January 14, 2021, at 10:50 AM EST. A live audio webcast will be available on the company's Investor Relations website, with a replay accessible for 30 days post-event. Constellation is focused on developing innovative therapies targeting gene expression to address significant medical needs in cancer patients, emphasizing their ongoing work with BET inhibitor CPI-0610 and EZH2 inhibitor CPI-0209.
Constellation Pharmaceuticals (Nasdaq: CNST) presented promising results from the Phase 2 MANIFEST and Phase 3 MANIFEST-2 clinical trials for CPI-0610 at the ASH Annual Meeting. In the first-line treatment, 67% of 63 patients achieved a ≥35% spleen volume reduction at 24 weeks. CPI-0610 showed activity as both a monotherapy and in combination with ruxolitinib, indicating potential disease-modifying effects. The company has initiated the global Phase 3 MANIFEST-2 study in JAK-inhibitor-naïve patients, advancing its investigational therapy towards treating myelofibrosis.
Constellation Pharmaceuticals (Nasdaq: CNST) will hold a virtual analyst/investor event on December 7, 2020, at 8:00 AM EDT to discuss the MANIFEST clinical trial data for CPI-0610 presented at the 62nd ASH Annual Meeting. The event will cover clinical data from 50-60 first-line and 90-100 second-line myelofibrosis patients and include a panel discussion with notable physicians. MANIFEST is a Phase 2 trial targeting myelofibrosis, evaluating CPI-0610's efficacy alongside ruxolitinib, focusing on spleen volume reduction and transfusion independence.
Constellation Pharmaceuticals reported its Q3 2020 financial results, showing a net loss of $33.8 million, up 59.7% year-over-year. R&D expenses rose 56.7% to $25.4 million, reflecting increased clinical trial costs, while G&A expenses increased 65% to $7.9 million. Cash and marketable securities totaled $489.4 million as of September 30, 2020, sufficient to fund operations into mid-2023. The company plans to present new data on CPI-0610 at the upcoming ASH meeting, aiming to address unmet needs in myelofibrosis treatment.
Constellation Pharmaceuticals will host a conference call on October 29, 2020, at 8:00 AM EDT to discuss its third quarter 2020 results and clinical progress. The call is open to the public and can be accessed via the Investor Relations section of their website. The company specializes in developing therapeutics targeting gene expression to address significant medical needs in cancer patients. Their pipeline includes the BET inhibitor CPI-0610 for myelofibrosis and the EZH2 inhibitor CPI-0209 for various cancers.
Constellation Pharmaceuticals (Nasdaq: CNST) will participate in two virtual investor conferences. CEO Jigar Raythatha will present at the H.C. Wainwright Global Investment Conference on September 14 at 1:00 PM EDT, and at the Cantor Global Healthcare Conference on September 17 at 1:20 PM EDT. Live audio webcasts will be available on their Investor Relations website, with replays accessible for 30 days post-presentation. The company focuses on developing therapeutics that modulate gene expression, addressing serious medical needs in cancer treatment.
Constellation Pharmaceuticals will host a conference call on August 5, 2020, at 8:00 AM EDT to discuss its Q2 2020 results and updates on clinical programs. Interested parties can access the live webcast through the Investor Relations section of their website. The company focuses on developing novel therapeutics for cancer, particularly utilizing epigenetic modifications. Their lead candidates include the BET inhibitor CPI-0610 for myelofibrosis and the EZH2 inhibitor CPI-0209 for other cancers.
Constellation Pharmaceuticals (Nasdaq: CNST) has priced an underwritten public offering of 5,500,000 shares at $35.00 each, totaling $192.5 million in gross proceeds before fees. The offering is set to close on June 19, 2020. An additional 825,000 shares may be purchased by underwriters within 30 days. This offering is being conducted under a previously filed shelf registration statement with the SEC. J.P. Morgan, Jefferies, Cowen, and RBC Capital Markets are the lead financial managers for this offering.
